ArticlePLoS pathogens2018
Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens.
Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 205 citations in OpenAlex.
- Metallo-beta-lactamase α-helix fragment modified peptide N10 is a multifunctional antimicrobial peptide.Microbiology spectrum · 2026Article
- Targeting the stringent response alters gene expression and extracellular vesicle RNA inMicrobiology spectrum · 2026Article
- Potential of Antimicrobial Peptide Synergies for Combating Infectious Diseases in Aquaculture: A Review.Animals : an open access journal from MDPI · 2026Review
- [In vitro and in vivo antibacterial effects of the mitochondrial antioxidant Visomitin againstZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Cloxiquine exerts bactericidal activity against Enterococcus faecalis through disruption of proton motive force and induction of reactive oxygen species.BMC microbiology · 2026Article
- D-amino acid substitution and cyclization enhance the stability and antimicrobial activity of arginine-rich peptides.Microbiology (Reading, England) · 2026Article
- Inhaled Antibiotic and Biologic Formulations TargetingPharmaceutics · 2026Review
- Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026Review
- DesHDAP2 Shows Significant Synergy with Conventional Antibiotics, Despite Its Relatively Low Potency.ACS omega · 2025Article
- Modern therapeutic strategies to mitigate biofilm-associated infection in livestock organisms.Antonie van Leeuwenhoek · 2025Review
- Tutorial: guidelines for the use of machine learning methods to mine genomes and proteomes for antibiotic discovery.Nature protocols · 2025Review
- Synthetic host defense peptide inhibits SARS-CoV-2 replicationAntimicrobial agents and chemotherapy · 2025Article
- A biofilm-targeting lipo-peptoid to treatBiofilm · 2025Article
- DJK-5, an anti-biofilm peptide, increases Staphylococcus aureus sensitivity to colistin killing in co-biofilms with Pseudomonas aeruginosa.NPJ biofilms and microbiomes · 2025Article
- Drug repurposing of Nifuratel against methicillin-resistantFrontiers in cellular and infection microbiology · 2025Article
- Evaluating the Antimicrobial Efficacy of a Designed Synthetic peptide against Pathogenic Bacteria.Journal of microbiology and biotechnology · 2024Article
- Proline-Modified RWn Peptides: Enhanced Antifungal Efficacy and Synergy with Conventional Antibiotics for Combating Resistant Fungal Infections.ACS omega · 2024Article
- Antibacterial and Anti-Inflammatory Activity of Branched Peptides Derived from Natural Host Defense Sequences.Journal of medicinal chemistry · 2024Article
- Article
- A role for the stringent response in ciprofloxacin resistance in Pseudomonas aeruginosa.Scientific reports · 2024Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
With the antibiotic development pipeline running dry, many fear that we might soon run out of treatment options. High-density infections are particularly difficult to treat due to their adaptive multidrug-resistance and currently there are no therapies that adequately address this important issue. Here, a large-scale in vivo study was performed to enhance the activity of antibiotics to treat high-density infections caused by multidrug-resistant Gram-positive and Gram-negative bacteria. It was shown that synthetic peptides can be used in conjunction with the antibiotics ciprofloxacin, meropenem, erythromycin, gentamicin, and vancomycin to improve the treatment outcome of murine cutaneous abscesses caused by clinical hard-to-treat pathogens including all ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae) pathogens and Escherichia coli. Promisingly, combination treatment often showed synergistic effects that significantly reduced abscess sizes and/or improved clearance of bacterial isolates from the infection site, regardless of the antibiotic mode of action. In vitro data suggest that the mechanisms of peptide action in vivo include enhancement of antibiotic penetration and potential disruption of the stringent stress response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.